ENSPRYNG
As listed in the register: ENSPRYNG 120 mg SOLUCION INYECTABLE EN JERINGA PRECARGADA
120 mg · solución inyectable en jeringa precargada
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Satralizumab
- Made by
- Roche Registration Gmbh
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
CanadaNo exact match for this strength and form
Netherlands1 matching products
SwitzerlandNo exact match for this strength and form
Details
| Made by | Roche Registration Gmbh |
|---|---|
| Active substance | Satralizumab |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 120 mg |
| Form | solución inyectable en jeringa precargada |
| Classification | L04AC19 · Cancer treatments and immune-system medicines |
| Route | vía subcutánea |
| Marketed | Yes, according to the register |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Name in the register | ENSPRYNG 120 mg SOLUCION INYECTABLE EN JERINGA PRECARGADA |
| Nº Registro | 1211559001 |
Source: CIMA — Centro de Información online de Medicamentos · 2026-09-30 · not reviewed by a clinician
Fuente: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA. Reuse terms: Aviso legal AEMPS.